Europe

Sanofi has been hoping to secure approval from the U.S. Food and Drug Administration for its dengue vaccine, but a mixed review from a panel of experts could sink the chances of a green light for the medication.

After Allergan reported that its late-stage adjunctive treatment for major depressive disorder failed to distinguish itself against placebo, hedge fund investor Appaloosa LP is again calling on the Ireland-based company to make some changes to its board of directors, including tapping a new chairman.

Often, patients prefer oral medications over receiving an injection or infusion, but daily pills sometimes result in compliance problems. In the case of this combination injection, it would, if approved, require patients to visit a clinic or physician once a month for the shot.

MorphoSys AG provided updates on L-MIND and B-MIND, its two ongoing clinical trials of the investigational Fc- enhanced anti-CD19 antibody MOR208 in patients with relapsed or refractory diffuse large B cell lymphoma, who are not eligible for high-dose chemotherapy and autologous stem cell transplantation.

Significant Progress with Novel Diabetic Eye Disease Portfolio

Prospective drug found by testing in human heart muscle grown from stem cells

Evotec AG announced that its management will be presenting at and attending the following upcoming conferences:

Strategic Senior Appointment Spearheads Compelling Work Culture for Continued Success

Auris Medical Holding AG announced that it will provide a business update and report its financial results for the fourth quarter and full year 2018 on Thursday, March 14, 2019.

Medtronic Global Holdings S.C.A. has closed a registered public offering of €500,000,000 principal amount of Floating Rate Senior Notes due 2021, €1,500,000,000 principal amount of 0.000% Senior Notes due 2021, €1,500,000,000 principal amount of 0.375% Senior Notes due 2023, €1,500,000,000 principal amount of 1.125% Senior Notes due 2027, €1,000,000,000 principal amount of 1.625% Senior Notes due 2031 and €1,000,000,000 principal amount of 2.250% Senior Notes due 2039.